Danaher Beat Earnings Estimates, so Why Are Investors Still Concerned About Growth?

Danaher Corporation reported mixed second-quarter results, beating earnings estimates and raising adjusted EPS guidance, but experiencing weaker-than-expected bioprocessing revenue and a reduced full-year core revenue growth outlook. This has led to investor concern despite strong underlying demand in its Life Sciences business. Investors are now watching for bioprocessing order growth, revenue shifts into the next year, and continued execution in the life sciences segment to determine if the company can meet its updated growth expectations.